We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Auris (EARS) Expands Pipeline with Intranasal Betahistine
Read MoreHide Full Article
Shares of Auris Medical Holding AG was up 2.6% after the company announced that it has added AM-125, a third clinical-stage program to its pipeline, which allowed it to expand into the field of vestibular disorders.
A look at Auris’ share price movement over the past one year shows that the stock has underperformed the Zacks classified Medical-Drugs industry. Specifically, the company’s stock tumbled 71.8% during this period, while the industry declined 2%.
Coming back to the latest news, Auris will develop betahistine dihydrochloride as a spray formulation for the intranasal treatment of Meniere's disease and vestibular vertigo.
Note that the company had entered into an agreement with Otifex Therapeutics Pty. Ltd. to purchase various assets related to intranasal betahistine, including preclinical and clinical data, and certain intellectual property rights. Auris plans to initiate a phase I study on the candidate in 2017.
Betahistine, a small molecule drug which acts as a partial histamine H1-receptor agonist and a H3-receptor antagonist, is approved (oral formulation) for the treatment of Meniere's disease and vestibular vertigo in more than 80 countries. Betahistine has, however, not been approved in the U.S.
According to the National Institute of Deafness and Other Communication Disorders, over 600,000 adults in the U.S. are currently diagnosed with Meniere's disease. Note that there is no therapy approved for Meniere's disease in the U.S., while treatment options for vestibular disorders are very limited in the region.
Addition of AM-125 to Auris’s pipeline is a strategic move for its existing projects. Going forward, we expect investors to focus on further updates from the company on the phase I study.
Auris currently carries a Zacks Rank #3 (Hold). Some better-ranked stocks in the health care sector include Sucampo Pharmaceuticals, Inc. , Sunesis Pharmaceuticals and Eli Lilly and Company (LLY - Free Report) . While Sucampo sports a Zacks Rank #1 (Strong Buy), Lilly and Sunesis carry a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Sucampo’s earnings estimates have increased 10.1% for 2017 over the last 60 days, while Sunesis’ loss estimates narrowed 8.80% for 2017. Meanwhile, Eli Lilly’s earnings estimates are 1.6% for 2017 in the last 60 days.
Zacks' Top Investment Ideas for Long-Term Profit
How would you like to see our best recommendations to help you find today’s most promising long-term stocks? Starting now, you can look inside our portfolios featuring stocks under $10, income stocks, value investments and more. These picks, which have double and triple-digit profit potential, are rarely available to the public. But you can see them now. Click here >>
Unique Zacks Analysis of Your Chosen Ticker
Pick one free report - opportunity may be withdrawn at any time
Image: Bigstock
Auris (EARS) Expands Pipeline with Intranasal Betahistine
Shares of Auris Medical Holding AG was up 2.6% after the company announced that it has added AM-125, a third clinical-stage program to its pipeline, which allowed it to expand into the field of vestibular disorders.
A look at Auris’ share price movement over the past one year shows that the stock has underperformed the Zacks classified Medical-Drugs industry. Specifically, the company’s stock tumbled 71.8% during this period, while the industry declined 2%.
Coming back to the latest news, Auris will develop betahistine dihydrochloride as a spray formulation for the intranasal treatment of Meniere's disease and vestibular vertigo.
Note that the company had entered into an agreement with Otifex Therapeutics Pty. Ltd. to purchase various assets related to intranasal betahistine, including preclinical and clinical data, and certain intellectual property rights. Auris plans to initiate a phase I study on the candidate in 2017.
Betahistine, a small molecule drug which acts as a partial histamine H1-receptor agonist and a H3-receptor antagonist, is approved (oral formulation) for the treatment of Meniere's disease and vestibular vertigo in more than 80 countries. Betahistine has, however, not been approved in the U.S.
According to the National Institute of Deafness and Other Communication Disorders, over 600,000 adults in the U.S. are currently diagnosed with Meniere's disease. Note that there is no therapy approved for Meniere's disease in the U.S., while treatment options for vestibular disorders are very limited in the region.
Addition of AM-125 to Auris’s pipeline is a strategic move for its existing projects. Going forward, we expect investors to focus on further updates from the company on the phase I study.
Auris Medical Holding AG Price and Consensus
Auris Medical Holding AG Price and Consensus | Auris Medical Holding AG Quote
Zacks Rank & Key Picks
Auris currently carries a Zacks Rank #3 (Hold). Some better-ranked stocks in the health care sector include Sucampo Pharmaceuticals, Inc. , Sunesis Pharmaceuticals and Eli Lilly and Company (LLY - Free Report) . While Sucampo sports a Zacks Rank #1 (Strong Buy), Lilly and Sunesis carry a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Sucampo’s earnings estimates have increased 10.1% for 2017 over the last 60 days, while Sunesis’ loss estimates narrowed 8.80% for 2017. Meanwhile, Eli Lilly’s earnings estimates are 1.6% for 2017 in the last 60 days.
Zacks' Top Investment Ideas for Long-Term Profit
How would you like to see our best recommendations to help you find today’s most promising long-term stocks? Starting now, you can look inside our portfolios featuring stocks under $10, income stocks, value investments and more. These picks, which have double and triple-digit profit potential, are rarely available to the public. But you can see them now. Click here >>